Oura's $625 Million Bet on Counsel Health: Strategic Pivot or Valuation Hail Mary?

Oura is attempting a high-stakes pivot into the primary care space, but the timing suggests this is less about organic growth and more about stabilizing a company in turmoil. As TechCrunch first reported on Tuesday, Oura announced it is acquiring Counsel Health, an AI-native primary care startup, for $625 million. While the company frames this as an expansion of its health ecosystem, the move arrives amidst a series of red flags that suggest Oura is scrambling to justify its current valuation.

**Opinion: The Valuation Gap** In my view, this acquisition looks less like a calculated strategic expansion and more like a desperate attempt to justify a valuation that the public markets have already rejected. Just a few weeks ago, Oura indefinitely postponed an IPO that could have raised up to $2.2 billion, citing "uncertainty in the IPO market." When the public market refuses to validate a company's price tag, the typical corporate playbook is to acquire growth and "AI-native" capabilities to create a new narrative. By absorbing Counsel Health, Oura isn't just buying a service; it's buying a reason for investors to keep believing in an $11 billion valuation—a figure reached following a $900 million late-stage funding round in October 2025.

**The Deal Details** According to reporting from TechCrunch, Counsel Health operates as an AI-powered healthcare platform that blends a chat-based medical experience with access to licensed physicians. The two companies had already begun integrating in June, allowing Oura users to utilize Counsel's medical AI for personalized advice and connect with physicians directly within the Oura app.

Under the terms of the deal, Oura intends to expand this partnership into preventative care, acute care, and specialty and chronic care. Oura CEO Tom Hale stated in a press release that the integration allows members to take action on their health through prescriptions, lab results, and referrals. Counsel Health CEO Muthu Alagappan will join Oura as the chief clinical AI officer, and Bloomberg reports that Counsel's 70 employees will also join the company. The deal is projected to wrap up by the close of 2027.

**A Market Under Pressure** Oura's urgency is likely driven by a tightening grip on the wearable market. While TechCrunch notes that Oura has dominated the smart ring sector for years, the company is now facing emerging rivals such as Ultrahuman and RingConn. As the hardware moat shrinks, Oura is betting that moving up the value chain into clinical care will provide the stickiness it needs to maintain its lead.

**The Financials** Despite the IPO setback, Oura's reported growth numbers remain aggressive. TechCrunch reports that for the quarter ended September 30, Oura's revenue grew 153% year-over-year to $533 million. For the full fiscal year 2026, the company generated approximately $1.75 billion in revenue, representing a 92% year-over-year increase.

Counsel Health itself was a lean operation prior to this exit. According to TechCrunch, GV and Andreessen Horowitz (a16z) led a $25 million Series A round for the startup one year ago. PitchBook estimates the company's total funding prior to the acquisition was $36 million. Following the deal, Oura says Counsel will continue to serve existing and new enterprise partners, aiming to scale the AI-native care model beyond Oura's own membership base.